Stratasys Ltd. (NASDAQ: SSYS) has filed a shelf registration statement with the U.S. Securities and Exchange Commission to allow it to issue sell an unspecified number of ordinary shares, warrants, and debt securities. At the same time the firm filed a Form 424 registering 6.93 million shares for sale at a maximum aggregate price of $768 million. The maximum per share price is given as $110.85.
About 3.92 million of the registered shares are were issued by Stratasys to and are now owned by shareholders of MakerBot, a maker of desktop 3D printers that Stratasys acquired in June for $400 million. The remaining 3.01 million shares included in this registration statement are intended to pay for potential further earnouts and payments to MakerBot stakeholders. Stratasys will receive no proceeds from the stakeholders��sale of these shares.
Since The ExOne Co. (NASDAQ: XONE)) came public in February, shares of Stratasys have risen about 37% compared with a rise of about 47% in the shares of peer 3D Systems Inc. (NYSE: DDD). The big gainer has been ExOne, up about 160% since coming public.
5 Best Diversified Bank Stocks To Watch For 2015: Trinity Industries Inc.(TRN)
Trinity Industries, Inc. provides products and services to the industrial, energy, transportation, and construction sectors primarily in the United States, Canada, Mexico, the United Kingdom, Singapore, and Sweden. The company?s Rail Group manufactures and sells railcars, including auto carrier, box, gondola, hopper, intermodal, specialty, and tank cars; and railcar components, such as couplers and axles. This group also offers repair and coating services. It primarily serves railroads, leasing companies, and industrial shippers of various products. Trinity Industries? Railcar Leasing and Management Services group leases tank cars and freight cars to industrial shippers and railroads operating in petroleum, chemical, agricultural, and energy industries with a fleet of 54,595 owned or leased railcars; provides management and administrative services; and manages railcar fleets on behalf of third parties. The company?s Construction Products group produces ready mix concret e; produces and distributes construction aggregates, including crushed stone, sand and gravel, asphalt rock, and specialty sands and gravel; manufactures highway products and other steel products for infrastructure related projects; supplies ready mix concrete; and provides hot-dip galvanizing services for fabricated steel materials. It primarily serves contractors and subcontractors in the construction and foundation industry. Trinity Industries? Inland Barge group manufactures inland barges; and fiberglass reinforced lift covers. It serves commercial marine transportation companies. The company?s Energy Equipment group manufactures structural wind towers, tank containers, and tank heads for pressure vessels; fertilizer containers; and tank heads for non-pressure vessels, LPG tanks, and utility, traffic, and lighting structures. It serves turbine producers, as well as industrial plants, utilities, residences, and small businesses. The company was founded in 1933 and is he adquartered in Dallas, Texas.
Advisors' Opinion:- [By Aaron Levitt]
Finally, any new tank-car regulation will benefit those firms that actually build and supply all those new cars. So our last pick in the wide world of railroad stocks is�Trinity Industries (TRN). The firm already has seen its tank-car order backlog surge so much — currently sitting at 40,000 cars — that it has shifted much of its capacity at its wind turbine tower business towards the manufacture of rail cars.
- [By Eric Volkman]
Trinity Industries (NYSE: TRN ) is rolling a higher dividend down the rails. The company has declared a distribution of $0.13 per share of its common stock. This will be paid on July 31 to shareholders of record as of July 15.�That amount represents an 18% improvement over the previous payout, which was handed out at the end of April and totaled $0.11 per share.
- [By Shauna O'Brien]
On Friday, Trinity Industries Inc (TRN) announced that it has raised its dividend by 15.4%.
The company’s board has approved an increase in its quarterly dividend from 13 cents to 15 cents per share, or 60 cents annually.
The dividend will be paid on October 31 to shareholders of record on October 15. The stock will go ex-dividend on October 10.
Trinity Industries shares were mostly flat during premarket trading Friday. The stock is up 20% YTD.
Hot Gas Utility Stocks To Watch Right Now: Swift Transportation Company(SWFT)
Swift Transportation Company, through its subsidiary, Swift Transportation Co., LLC, operates as a multi-faceted transportation services company and truckload carrier in North America. The company offers its truckload services through dry van, temperature-controlled, flatbed, and specialized trailers; and rail intermodal services. It also provides freight brokerage and logistics management services to other trucking companies, as well as leases tractors and offers repair services. As of December 31, 2011, the company operated a tractor fleet of approximately 15,900 units, including 11,900 tractors driven by company drivers and 4,000 owner-operator tractors; 50,600 trailers; and 6,200 intermodal containers in the United States and Mexico. It serves various industries, such as retail, discount retail, consumer products, food and beverage, manufacturing, and transportation and logistics industries. The company, formerly known Swift Holdings Corp., and was founded in 1966 and is headquartered in Phoenix, Arizona.
Advisors' Opinion:- [By Seth Jayson]
Swift Transportation (NYSE: SWFT ) reported earnings on July 24. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Swift Transportation met expectations on revenues and beat expectations on earnings per share. - [By Sean Williams]
For this week's round of "Better Know a Stock," I'm going to take a closer look at Swift Transportation (NYSE: SWFT ) .
What Swift Transportation does
Swift is a transportation services trucking and intermodal company in North America. The company primarily transports discounted consumer goods, perishable and non-perishable foods, and manufactured goods. As of the end of 2012 Swift operated 15,300 tractors, 52,800 trailers, and had 8,700 intermodal containers.
Hot Gas Utility Stocks To Watch Right Now: Ryanair (RYAAY)
Ryanair Holdings plc (Ryanair Holdings), incorporated in 1996, is a holding company for Ryanair Limited (Ryanair). Ryanair operates a low-cost, scheduled-passenger airline serving short-haul, point-to-point routes between Ireland, the United Kingdom, Continental Europe, and Morocco. As of June 30, 2012, the Company offered approximately over 1,500 scheduled short-haul flights per day serving approximately 160 airports largely throughout Europe with an operating fleet of 294 aircraft flying approximately 1,500 routes. Ryanair sells seats on a one-way basis. The Company also holds a 29.8% interest in Aer Lingus Group plc. As of June 30, 2012, Ryanair�� operating fleet was composed of 294 Boeing 737-800 aircraft, each having 189 seats. Ryanair�� fleet totaled 294 Boeing 737-800s at March 31, 2012. As of June 30, 2012, Ryanair owned and operated four Boeing 737-800 full flight simulators for pilot training. Ryanair provides ancillary services and engages in other activities connected with its core air passenger service, including non-flight scheduled services, Internet-related services, and the in-flight sale of beverages, food, and merchandise. As part of its non-flight scheduled and Internet-related services Ryanair incentivizes ground service providers at airports it serves to levy correct excess baggage charges for any baggage, which exceeds Ryanair�� published baggage allowances. Excess baggage charges are recorded as non-flight scheduled revenue. Ryanair distributes accommodation services and travel insurance through its Website. For hotel services, Ryanair has a contract with Hotelscombined PTY Ltd. (Hotelscombined), which operates a price comparison Website, pursuant to which Hotelscombined handles all aspects of such services marketed through Ryanair�� Website and pays a fee to Ryanair. Ryanair also has contracts with other accommodation providers that enable Ryanair to offer hostel, bed-and-breakfast, guesthouse, villa and apartment accommodation to its customers. In addition Ryanair has a contract with Hertz, pursuant to which Hertz handles all car rental services marketed through Ryanair�� Website or telephone reservation system. Ryanair also sells bus and rail tickets onboard its aircraft and through its Website. Ryanair also sells attractions and activities on its Website. Ryanair sells gift vouchers on its Website, which are also redeemable online. The Company has an contract with Webloyalty International Ltd, which offers Ryanair�� customers who have a United Kingdom, German or French billing address a retail discount and cash-back program. Ryanair has agreements, pursuant to which the Company promotes Ryanair-branded credit cards issued by MBNA, GE Money, Access Prepaid and Banco Santander on its Internet site. The MBNA agreement relates to Irish residents only, the GE Money agreement relates to Swedish and Polish residents only and the Banco Santander agreement relates to United Kingdom residents only. During the fiscal year ended March 31, 2012, Ryanair rolled out handheld Electronic Point of Sale (EPOS) devices across its route network. These EPOS devices replaced manual and paper based systems on board the aircraft. The EPOS device enables cabin crew to sell and record their on-board sales transactions. The EPOS device also issues bus and rail tickets and tickets for tourist attractions. The Company also offers reserved seating in twenty-one extra legroom seats on each aircraft for a fee on certain routes. Ryanair provides its own aircraft and passenger handling and ticketing services at Dublin Airport. Third parties provide these services to Ryanair at other airports it serves. Servisair plc provides Ryanair�� ticketing, passenger and aircraft handling, and ground handling services at airports in Ireland and the United Kingdom(excluding London (Stansted) Airport where these services are provided by Swissport Ltd.), while similar services in continental Europe are provided by the local airport authorities, either directly or through sub-contractors. Advisors' Opinion:- [By Jon C. Ogg]
Ryanair Holdings PLC (NASDAQ: RYAAY) was downgraded to Neutral from Buy at UBS.
Verizon Communications Inc. (NYSE: VZ) was reiterated as Buy and on the Focus List with a $59 price target at Argus, and it was raised to Outperform at RW Baird.
- [By Luke Jacobi]
Ryanair Holdings plc (NASDAQ: RYAAY) shares were up nearly 6.97 percent into the close to $54.53 after the company reported full-year results. Ryanair's net profit for the year ended March 31 slipped to 522.8 million euros ($716 million), versus a year-ago profit of 569.3 million euros.
Hot Gas Utility Stocks To Watch Right Now: CyrusOne Inc (CONE)
CyrusOne Inc., incorporated on July 31, 2012, is a owner, operator and developer of enterprise-class, carrier-neutral data center properties. Enterprise-class, carrier-neutral data centers are purpose-built facilities with redundant power, cooling and telecommunications systems and that are not network-specific, enabling customer interconnectivity to a range of telecommunications carriers. The Company provides mission-critical data center facilities that protect operation of information technology (IT) infrastructure for approximately 500 customers. As of September 30, 2012, its customers included nine of the Fortune 20 and 108 of the Fortune 1000 or private or foreign enterprises of equivalent size. On July 31, 2012, the Company�� operating partnership, CyrusOne LP, was formed. On July 31, 2012, CyrusOne GP, the general partner of the Company�� operating partnership, was formed as a trust.
As of September 30, 2012, the Company�� property portfolio included 23 operating data centers in nine markets: Austin, Chicago, Cincinnati, Dallas, Houston, London, San Antonio, Singapore, and South Bend providing approximately 1,630,000 net rentable square feet (NRSF) and powered by approximately 125 megawatts of utility power. The Company owns nine of the buildings in which its data center facilities are located. It leases the remaining 14 buildings, which account for approximately 600,000 NRSF. The Company also has 379,000 NRSF under development at three data centers in three markets (Dallas, Houston and Phoenix) and 762,000 NRSF of additional powered shell space under roof and available for development. In addition, it has approximately 146 acres of land that are available for future data center facility development. Along with its primary product offering, leasing of colocation space, its customers are interested in its ancillary office and other space.
As of September 2012, the Company added 36,000 Colocation Space (CSF) at its Westover Hills Blvd (San Antonio) facility, 47,0! 00 CSF at its Frankford Road (Carrollton) facility and 15,000 CSF at its Westway Park Blvd (Houston West) facility. The Company�� portfolio of properties consists primarily of data centers geographically concentrated in cities in Ohio and Texas, which comprised 38% and 59%, respectively, of its annualized rent as of September 30, 2012.
Advisors' Opinion:- [By Dan Caplinger]
But IBM has had to deal with increasing competition to its business model. Business software giant Oracle (NYSE: ORCL ) has finally reached an impressive execution milestone in the strategy it began four years ago with its acquisition of Sun Microsystems: Oracle's new chips and server products managed to best Big Blue's offerings in independent benchmark testing. Smaller companies will increasingly find their own niche roles in the big-data space as well. For instance, CyrusOne (NASDAQ: CONE ) , which got spun off from Cincinnati Bell recently, is seeking to make a name for itself in the data-storage infrastructure space. Despite its hefty debt load, CyrusOne has huge growth potential to capitalize on the growing need for data-storage centers, and it has the benefits of tax-favored real-estate investment trust status to boot.
Hot Gas Utility Stocks To Watch Right Now: Boston Scientific Corp (BSX)
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2011, its products were offered for sale by seven core businesses: Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women�� Health, Neuromodulation, and Electrophysiology. In January 2011, it completed the acquisition of Intelect Medical, Inc. In January 2011, it completed the acquisition of Sadra Medical, Inc. In March 2011, the Company completed the acquisition of Atritech, Inc. In February 2011, it announced the acquisitions of S.I. Therapies and ReVascular Therapeutics, Inc. In January 2011, the Company sold its Neurovascular business to Stryker Corporation. In June 2012, the Company acquired Cameron Health, Inc. of San Clemente, California and, as a result, added to its product portfolio subcutaneous implantable cardioverter defibrillator, called the S-ICD System.
Interventional Cardiology
The Company offers coronary stent product. Coronary stents are tiny, mesh tubes used in the treatment of coronary artery disease, which are implanted in patients to prop open arteries and facilitate blood flow to and from the heart. The Company offers a two-drug platform strategy with its paclitaxel-eluting and everolimus-eluting stent system offerings, and it offers a range of stent sizes. The Company markets its next-generation internally-developed and self-manufactured PROMUS Element stent system in the United States, its Europe/Middle East/Africa (EMEA) region and certain Inter-Continental countries, including China and India. It markets the PROMUS everolimus-eluting stent system, supplied to the Company by Abbott Laboratories, in Japan. It also markets its TAXUS paclitaxel-eluting stent line, including its third-generation TAXUS Element paclitaxel-eluting stent system in the U.nited States, Japan, EMEA and certain Inter-Continental countries.
The Compa! ny markets a line of products used to treat patients with atherosclerosis, a principal cause of coronary artery obstructive disease. Its product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA). The Company markets a family of intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels. The iLab Ultrasound Imaging System continues as its flagship console and is compatible with its line of imaging catheters. The system is designed to enhance the diagnosis and treatment of blocked vessels and heart disorders. Sadra is developing a repositionable and retrievable device for transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis. The Lotus Valve System consists of a stent-mounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve. Atritech has developed a device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke. The WATCHMAN Left Atrial Appendage Closure Technology, developed by Atritech, is the first device proven in a randomized clinical trial to offer an alternative to anticoagulant drugs, and is approved for use in CE Mark countries.
Cardiac Rhythm Management
The Company develops, manufactures and markets a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including Implantable cardioverter defibrillator (ICD) systems used to detect and treat abnormally fast heart rhythms (tachycardia) that could result in sudden cardiac death, including implantable cardiac resynchronization therapy defibrillator (CRT-D) systems used to treat heart failure, and implantable pacemaker systems used to manage slow or irregular heart rhyth! ms (brady! cardia), including implantable cardiac resynchronization therapy pacemaker (CRT-P) systems used to treat heart failure. Its product offerings include its COGNIS cardiac resynchronization therapy defibrillator (CRT-D), its TELIGEN ICD systems and its ALTRUA family of pacemaker systems. During 2011, it began the United States launch of its next-generation line of defibrillators, INCEPTA, ENERGEN and PUNCTUA.
Endoscopy
The Company markets a range of products to diagnose, treat and ease a variety of digestive diseases, including those affecting the esophagus, stomach, liver, pancreas, duodenum, and colon. Common disease states include esophagitis, portal hypertension, peptic ulcers as well as esophageal, biliary, pancreatic and colonic cancer. The Company offers the Radial Jaw 4 Single-Use Biopsy Forceps, which are designed to enable collection of large high-quality tissue specimens without the need to use large channel therapeutic endoscopes. Its exclusive line of RX Biliary System devices are designed to provide greater access and control for physicians to diagnose and treat challenging conditions of the bile ducts, such as removing gallstones, opening obstructed bile ducts and obtaining biopsies in suspected tumors. The Company also markets the Spyglass Direct Visualization System for direct imaging of the pancreatico-biliary system. The Spyglass System is a single-operator cholangioscopy device that offers clinicians a direct visualization of the pancreatico-biliary system and includes supporting devices for tissue acquisition, stone management and lithotripsy. Its products also include the WallFlex family of stents, in particular, the WallFlex Biliary line and WallFlex Esophageal line; and in 2011, the Company launched its Advanix Biliary Plastic Stent System and the Expect Endoscopic Ultrasound Aspiration Needle in the United States and certain international markets. Its Resolution Clip Device is an endoscopic mechanical clip designed to treat gastrointestinal bleeding.
T! he Company markets devices to diagnose, treat and ease pulmonary disease systems within the airway and lungs. Its products are designed to help perform biopsies, retrieve foreign bodies from the airway, open narrowings of an airway, stop internal bleeding, and ease symptoms of some types of airway cancers. Its product line includes pulmonary biopsy forceps, transbronchial aspiration needles, cytology brushes and tracheobronchial stents used to dilate narrowed airway passages or for tumor management. Asthmatx, Inc. designs, manufactures and markets a less-invasive, catheter-based bronchial thermoplasty procedure for the treatment of severe persistent asthma. The Alair Bronchial Thermoplasty System, developed by Asthmatx, has both CE Mark and Food and Drug Administration (FDA) approval and is the first device-based asthma treatment approved by the FDA.
Peripheral Interventions
The Company sells various products designed to treat patients with peripheral disease, including a line of medical devices used in percutaneous transluminal angioplasty and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. In 2010 and 2011, it launched several of its products internationally, including the EPIC self-expanding nitinol stent system in certain international markets, and the Carotid WALLSTENT stent system in Japan. The Company launched three new peripheral angioplasty balloons in 2011, including its next-generation Mustang percutaneous transluminal angioplasty (PTA) balloon, its Coyote balloon catheter, a highly deliverable and ultra-low profile balloon dilatation catheter designed for a range of peripheral angioplasty procedures and its Charger PTA Balloon Catheter, a 0.035 inch percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation, as well as conventional balloon angioplasty to open blocked peripheral arteries. The Company has commenced a limited ma! rket rele! ase of its OFFROAD re-entry catheter system in certain international markets, and in February 2012, it launched its TRUEPATH intraluminal CTO device in the United States.
The Company sells products designed to treat patients with non-vascular disease. Its non-vascular suite of products include biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company continues to market its extensive line of Interventional Oncology product solutions, including the Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. The Company�� FilterWire EZ Embolic Protection System is a filter designed to capture embolic material that may become dislodged during a procedure, which could otherwise travel into the microvasculature where it could cause a heart attack or stroke. It is commercially available in the United States, its EMEA region and certain Inter-Continental countries for multiple indications, including the treatment of disease in peripheral, coronary and carotid vessels. It is also available in the United States for the treatment of saphenous vein grafts and carotid artery stenting procedures.
Urology/Women�� Health
The Company�� Urology/Women�� Health division develops, manufactures and sells devices to treat various urological and gynecological disorders. The Company sells a variety of products designed to treat patients with urinary stone disease, stress urinary incontinence, pelvic organ prolapse and excessive uterine bleeding. The Company offers a line of stone management products, including ureteral stents, wires, lithotripsy devices, stone retrieval devices, sheaths, balloons and catheters.
The Company markets a range of devices for the treatment of conditions, such as female urinary incontinence, pelvic floor reconstruction (rebuilding of the anatomy to its original state), and ! menorrhag! ia (excessive menstrual bleeding). It offers a breadth of mid-urethral sling products, sling materials, graft materials, pelvic floor reconstruction kits, and suturing devices. The Company markets its Genesys Hydro ThermAblator (HTA) system, a next-generation endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. The Genesys HTA System features a smaller and lighter console, simplified set-up requirements, and an enhanced graphic user interface and is designed to improve operating performance.
Neuromodulation
The Company within its Neuromodulation business markets the Precision Spinal Cord Stimulation (SCS) system, used for the management of chronic pain. In 2011, the Company launched its Clik Anchor for its Precision Plus SCS System, a rechargeable SCS device for chronic pain management. During 2011, it received FDA approval for and launched the Infinion 16 Percutaneous Lead, a 16-contact percutaneous lead. The Company also markets the Linear 3-4 and Linear 3-6 Percutaneous Leads for use with its SCS systems, which are designed to provide physicians more treatment options for their chronic pain patients. Intelect Medical, Inc. is a development-stage company developing advanced visualization and programming for the Vercise system.
Electrophysiology
The Company within its Electrophysiology business develops less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart. Included in its product offerings are radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Its products include the Blazer and Blazer Prime line of temperature ablation catheters, designed to deliver enhanced performance, responsiveness, and durability. Its cooled ablation portfolio includes the closed-loop irrigated catheter on the market, the Chilli II cooled! ablation! catheter, and the newly launched Blazer Open-Irrigated ablation catheter with a Total Tip Cooling Design.
The Company competes with Abbott Laboratories, Medtronic, Inc., St. Jude Medical, Inc. and Johnson & Johnson.
Advisors' Opinion:- [By Sean Williams]
Shares of medical-device maker Boston Scientific (NYSE: BSX ) jumped 3.6% after the company announced on Friday that it had launched a clinical trial to evaluate if occipital nerve stimulation using its Precision System can safely treat chronic migraine when used with existing anti-migraine medications. Migraines are still a largely misunderstood disease, and the current medication available could definitely get better, leaving the door wide open for Boston Scientific should this trial prove fruitful. With Boston Scientific shares cresting $10 for the first time in three years shareholders are certainly pumped, but I'd reserve that optimism until its bottom line profits catch-up with its now loftier valuation.
- [By Dimitra DeFotis]
Colleague Dave Englander recommended taking profits in another medical device maker, Boston Scientific (BSX) in mid-August. At the time, he noted that stock was up 107% since his favorable recommendation had appeared, outpacing the Standard & Poor’s 500 Index by 80 points. He noted Boston Scientific faces competition from St. Jude and Medtronic (MDC), and he said that the market for stents and defibrillators has stabilized but is “not likely to grow meaningfully.” �(See “Time to Sell These Winners,” Aug. 14, subscription required.)
- [By Dan Carroll]
Boston Scientific (NYSE: BSX ) hasn't been as quick to jump on the bandwagon as St. Jude and Medtronic have, but this cardiovascular-focused firm won't be left behind. Facing struggling sales from its CRM and interventional cardiology businesses, Boston Scientific pushed into renal denervation with its purchase of Vessix Vascular late last year. While Vessix's V2 renal denervation system has a long way to go before being approved in the U.S., it has already earned European and Australian regulatory approval.
- [By Eric Volkman]
Boston Scientific (NYSE: BSX ) has made a strong move deeper into the business of electrophysiology -- the study of electrical phemomena, and how they are related to the functions of the body. The company announced�that it inked an agreement to purchase Bard EP, the electrophysiology division of C.R. Bard (NYSE: BCR ) . The price is $275 million in cash.
Hot Gas Utility Stocks To Watch Right Now: Delphi Financial Group Inc. (DFG)
Delphi Financial Group, Inc., together with its subsidiaries, provides integrated employee benefit services. The company operates in two segments, Group Employee Benefit Products and Asset Accumulation Products. The Group Employee Benefit Products segment provides disability, group life, and excess workers? compensation insurance products to small and mid-sized employers. It also offers travel accident, voluntary accidental death and dismemberment, group dental, and limited benefit health insurance products, as well as assumed workers? compensation and casualty reinsurance. This segment markets its group products to employer-employee groups and associations in various industries primarily through independent brokers and agents. The Asset Accumulation Products segment primarily offers fixed annuities, such as single premium deferred annuities, flexible premium annuities, and multi-year interest guarantee products to individuals through networks of independent insurance agen ts. The company also provides integrated disability and absence management services, including event reporting, leave of absence management, claims and case management, and return to work management. Delphi Financial Group, Inc. was founded in 1987 and is based in Wilmington, Delaware.
Advisors' Opinion:- [By Holly LaFon]
Some of Elliott Management�� top equity positions in the first quarter 2012 are Brocade Communications Systems (BRCD), Delphi Automotive (DFG), Iron Mountain (IRM) and News Corp. (NWS).
No comments:
Post a Comment